Welcome to our dedicated page for MOLECULAR PARTNERS news (Ticker: MOLN), a resource for investors and traders seeking the latest updates and insights on MOLECULAR PARTNERS stock.
Molecular Partners AG develops DARPin therapeutics, a class of custom-built protein drugs used in oncology-focused drug development. Company updates center on its clinical-stage and preclinical pipeline, including Radio-DARPin candidates for targeted radiopharmaceuticals, tumor-localized immune activation programs, and next-generation immune cell engagers for cancer.
Recurring developments include scientific conference presentations, peer-reviewed clinical data, preclinical research, partnership activity, annual financial results, and shareholder-meeting governance. Key program references include MP0712, a DLL3-targeting Radio-DARPin for small cell lung cancer and other DLL3-expressing neuroendocrine cancers; MP0317, a FAPxCD40 DARPin designed for tumor-localized CD40 activation; and Switch-DARPin and T cell engager candidates for solid tumors and hematologic cancers.
Molecular Partners (SIX: MOLN, NASDAQ: MOLN) reported Q1 2026 highlights, including initiation of clinical studies for MP0712 and MP0317 and progress across its DARPin pipeline.
The company held CHF 79 million in cash and short-term deposits as of March 31, 2026, with runway into late 2027.
Molecular Partners (NASDAQ: MOLN) will present oral talks on its lead Radio-DARPin candidate MP0712, a 212Pb-based DLL3-targeting therapeutic for small cell lung cancer, at three scientific meetings in May 2026: NCI SCLC Consortium (May 7), PEGS Boston (May 13) and Antibody & Engineering Therapeutics Basel (May 29).
Molecular Partners (NASDAQ: MOLN) published Phase 1 data in Nature Cancer for MP0317, a FAPxCD40 DARPin designed for tumor-localized CD40 activation. The Phase 1 dose‑escalation (46 patients) showed biomarker proof‑of‑mechanism, tumor microenvironment remodeling, a favorable safety profile up to the highest dose, and PK suitable for weekly or every‑3‑week dosing. An investigator‑initiated randomized Phase 2 in front‑line cholangiocarcinoma (N=75, 2:1 randomization, eight sites activated) is open with dosing ongoing.
Molecular Partners (NASDAQ: MOLN) will present three AACR 2026 posters with preclinical and early clinical data for novel DARPin candidates. MP0632 is a logic-gated Switch-DARPin T cell engager showing tumor regression in MSLN/EpCAM co-expressing models with limited activity on single-antigen tumors, suggesting a favorable therapeutic window. MP0712 is a 212Pb Radio-DARPin with high DLL3 affinity, half-life extension and promising biodistribution plus first patient imaging data; MP0712 is in a US Phase 1/2a trial for SCLC.
Presentations occur 4/20/2026 and 4/22/2026; posters to be posted after AACR.
Molecular Partners (SIX/NASDAQ: MOLN) reported that shareholders approved all Board proposals at the Annual General Meeting on April 14, 2026, including the election of Clare Fisher to the Board. Shareholders approved the 2025 IFRS consolidated financial statements and carried forward a net loss of CHF 57,853,768, increasing retained loss to CHF 257,293,925.
Board and management were granted discharge; several committee appointments and auditor and proxy re-elections were confirmed. Steven H. Holtzman did not stand for re-election after 12 years of service.
Molecular Partners (SIX: MOLN; NASDAQ: MOLN) published its invitation to the Annual General Meeting on April 14, 2026 in Schlieren, Switzerland and nominated Clare Fisher for election to the Board of Directors.
Long-serving director Steven H. Holtzman will not stand for re-election after 12 years of service. The company also published its 2026 financial calendar with key reporting dates.
Molecular Partners (NASDAQ: MOLN) presented preclinical data showing two Radio-DARPin candidates have highly comparable biodistribution when labeled with 177Lu or 203Pb, enabling isotope interchangeability. Imaging with 177Lu/203Pb may predict behavior of therapeutic isotopes 225Ac/212Pb. The company also announced an agreement with Eckert & Ziegler to support development and manufacturing of Radio-DARPins.
MP0712, a DLL3-targeted 212Pb candidate, is in an ongoing Phase 1/2a trial (NCT07278479); presentation delivered March 19–20, 2026.
Molecular Partners (NASDAQ: MOLN) will present three posters at the American Association for Cancer Research (AACR) Annual Meeting, April 17-22, 2026, in San Diego. The posters cover DARPin T cell engagers, data-driven tumor-antigen profiling, and a 212Pb Radio-DARPin candidate (MP0712) for SCLC.
Sessions occur April 20 and April 22 with poster numbers 1624, 2691, and 7197 in designated poster sections.
Molecular Partners (SIX/NASDAQ: MOLN) reported 2025 results and pipeline progress. Key clinical advances include the initiation of the Phase 1/2a study of MP0712 (DLL3, 212Pb) with initial imaging/dosimetry data and expected clinical readouts in 2026. The company ended 2025 with CHF 93.1M cash, funding operations into 2028, and a 2025 net loss of CHF 61.7M.
Other highlights: MP0726 advancing toward first-in-human imaging, a deal with Eckert & Ziegler for isotope access, ongoing Phase 2 investigator trial of MP0317 in cholangiocarcinoma, and an active MP0533 AML program with an update expected H1 2026.
Molecular Partners (SIX: MOLN; NASDAQ: MOLN) announced CEO Patrick Amstutz will present at two investor conferences in March 2026 and that the company will release its full-year 2025 financial results and Annual Report on March 12, 2026.
Fireside chats at TD Cowen (March 2) and Leerink Partners (March 9) will be available on the company investor website. The results release is scheduled for March 12 at 4:00 pm EDT (9:00 pm CET).